Tectonic Therapeutic is the latest venture undertaken by Harvard’s serial entrepreneur Timothy Springer, who co-led the series A round.

Tectonic Therapeutic, a US-based biotechnology spinout of Harvard University, has collected $80m in its series A round co-led by Prof Timothy Springer, one of its co-founders and faculty member at Harvard Medical School.
Vida Ventures and Polaris Partners co-led the round, which also attracted EcoR1 Capital.
Founded in 2019, Tectonic is working on G-protein-coupled receptors (GPCR)-targeted therapies. The proteins are a popular drug target due to their involvement in numerous bodily functions but their potential remains mostly untapped…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.